DEF 14A: CERo Therapeutics Seeks Reverse Split, Equity Plan Boost

CERo Therapeutics Holdings, Inc. calls a special meeting to approve a reverse stock split, preferred stock issuance, and an increase in its equity incentive plan to address Nasdaq listing requirements and fund operations.

Summary

• A Special Meeting of Stockholders will be held virtually on December 19, 2025, at 9:00 a.m. Pacific Time.
• Proposal No. 1 seeks approval for a reverse stock split of common stock, with a ratio between one-for-40 and one-for-150, to raise the per-share trading price and potentially regain Nasdaq listing. The current bid price on OTC Pink Sheets was $0.0990 per share on November 12, 2025.
• Proposal No. 2 requests approval for the issuance of common stock upon conversion of Series E convertible preferred stock, issued in an October 2025 private placement, at a price below Nasdaq's minimum price, to comply with Nasdaq Listing Rule 5635.
• Proposal No. 3 aims to increase the shares available under the 2024 Equity Incentive Plan by an additional 32,000,000 shares, bringing the total to 32,123,494 shares, to attract and retain key employees.
• Proposal No. 4 is for the approval of an adjournment of the Special Meeting, if necessary, to solicit further proxies for the other proposals.
• The Board of Directors unanimously recommends a 'FOR' vote on all four proposals.

Sentiment

Score: 2

Explanation: The filing outlines critical measures (reverse stock split, dilutive preferred stock conversion, increased equity plan) necessary to address severe challenges, including Nasdaq delisting and low stock price. While these actions are aimed at survival and future growth, they are reactive to a distressed situation and carry significant risks, particularly dilution and uncertainty regarding regaining Nasdaq listing.

Positives

• The company is actively pursuing measures, such as a reverse stock split, to regain compliance with Nasdaq's listing requirements, which could improve market accessibility and investor interest.
• The Board has flexibility to determine the exact ratio of the reverse stock split within a specified range (1-for-40 to 1-for-150), allowing for adaptation to market conditions.
• The proposed increase in the 2024 Equity Incentive Plan by 32,000,000 shares is intended to provide adequate long-term equity incentives to recruit and retain key employees, which is crucial for a development-stage biotech company.
• A private placement in October 2025 successfully raised approximately $2.25 million through the issuance of Series E Preferred Stock, with potential for an additional $4.75 million from future closings.

Negatives

• The company's common stock was suspended from Nasdaq trading on October 31, 2025, and now trades on the OTC Pink Sheets, indicating a significant decline in market standing.
• The current common stock price of $0.089 per share (as of November 14, 2025) is substantially below Nasdaq's $1.00 minimum bid price requirement.
• There is no assurance that the reverse stock split will result in a sustained increase in the per-share price or that the company will regain Nasdaq listing, as prior reverse stock splits have not prevented subsequent price declines.
• The issuance of common stock upon conversion of Series E preferred stock, especially at a potentially reduced conversion price (as low as $0.05), could lead to significant dilution for existing shareholders, potentially up to 36.9% of outstanding shares if converted at the Floor Price with the Required Premium.
• Failure to approve the issuance of common stock for Series E preferred stock (Proposal No. 2) could prevent the company from conducting future capital raising transactions at favorable prices, potentially leading to insufficient funds for operations, liquidation, or bankruptcy.
• The reverse stock split will increase the proportion of authorized but unissued shares, which could have anti-takeover effects and further dilute existing shareholders if these shares are issued without further stockholder approval.

Risks

• The reverse stock split may not result in a sustained increase in the per-share price of common stock or enable the company to regain Nasdaq listing.
• The market price per share of common stock after the reverse stock split may not rise proportionally to the reduction in the number of shares outstanding.
• The reverse stock split may not attract brokers and investors who typically avoid lower-priced stocks, nor may it increase the company's ability to attract and retain employees.
• The company is currently not in compliance with Nasdaq's minimum stockholders' equity requirement, and the reverse stock split will not address this issue.
• The issuance of additional authorized but unissued shares of common stock post-reverse split could dilute existing shareholders' ownership and voting power.
• The market price of common stock could decline further after the reverse stock split, potentially at a greater percentage than without the split.
• There is a negative perception of reverse stock splits among some investors, analysts, and market participants.
• A reduced number of shares outstanding post-split may impair liquidity for common stock, potentially reducing its value.
• Failure to approve Proposal No. 2 (Nasdaq Share Issuance (Series E) Proposal) could prevent the company from obtaining necessary financing, leading to insufficient resources to fund operations, potential liquidation, or bankruptcy.
• The company's ability to obtain additional cash and the sufficiency of existing cash, cash equivalents, and equity securities to fund future operating expenses and capital expenditure requirements are uncertain.
• Risks associated with the scope, progress, results, and costs of developing drug candidates (e.g., CER-1236) and conducting preclinical/clinical trials.
• Uncertainty regarding the timing and costs of obtaining and maintaining regulatory approval for drug candidates.
• The success of competing drugs, therapies, or other products that are or may become available.
• The impact of macroeconomic conditions and geopolitical turmoil on business and operations, including interest rates, inflationary pressures, and capital market disruptions.

Future Outlook

The company expects to conduct additional financing transactions through the remainder of 2025 and throughout 2026 to fund its planned business operations and clinical trials. It aims to advance its drug candidate CER-1236 into clinical development and intends to seek special designations or accelerated approvals for its drug candidates for various indications. If CER-1236 is approved, the company plans to grow a sales team for commercialization.

Management Comments

• "We are pleased to invite you to attend the 2025 Special Meeting of Stockholders."
• "Your vote is important. Whether or not you plan to virtually attend the Special Meeting, we encourage you to vote as soon as possible to ensure that your shares are represented."
• "Our primary objective in effectuating the Reverse Stock Split would be to attempt to raise the per-share trading price of our Common Stock to meet Nasdaq's listing requirements... and thereby potentially regain listing on Nasdaq."
• "The Board also believes that a higher stock price may help generate investor interest in the Company."
• "Our Board strongly believes that the Reverse Stock Split is necessary to regain listing on Nasdaq and to thereby provide us with a market for our Common Stock that is more accessible than our current market, OTC Pink Sheets."
• "We believe that enabling the Board to fix the specific ratio of the Reverse Stock Split within the stated range will provide us with the flexibility to implement it in a manner designed to maximize the anticipated benefits for our stockholders."
• "The compensation committee believes the number of shares of common stock available for issuance under the Plan is not sufficient to make the grants that will be needed over the next year to provide adequate long-term equity incentives to the Company's key employees."

Industry Context

The biotechnology industry is characterized by high research and development costs and a significant need for capital to fund clinical trials and regulatory processes. Companies in this sector often face challenges maintaining stock exchange listings, particularly if their stock price falls below minimum requirements due to development risks or market sentiment. Reverse stock splits and equity incentive plans are common tools used by biotech firms to address these issues, aiming to improve stock perception, attract institutional investors, and retain key scientific and management talent in a highly competitive environment.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Received a determination from the Nasdaq Hearings Panel on October 29, 2025, to deny the request for continued listing of common stock on Nasdaq and to suspend trading.
• Submitted a request for review of the Panel's decision by the Nasdaq Listing and Hearing Review Council, with delisting stayed pending resolution of the appeal.

Related Party Transactions

• A Collaboration and Option Agreement with an investor of Legacy CERo was in effect from March 3, 2020, to March 3, 2023, with no payments made in 2023.
• In February 2024 PIPE Financings, Daniel Corey (former CTO/Director) purchased $150,000 of Series A Preferred Stock, Atwood-Edminster Trust dtd 4-2-2000 (Brian G. Atwood, former CEO/Chairman, trustee) purchased $1,002,000, Chris Ehrlich (current Chairman/CEO) purchased $275,000, and Phoenix Biotech Sponsor, LLC (beneficial owner >5%) purchased $1,380,000.
• In a February 2025 Registered Direct Offering, Brian Atwood (director) purchased 25,510 Pre-Funded Warrants and accompanying Common Warrants for approximately $1 million.
• In the April 2025 Fourth PIPE Financing, Series D Preferred Stock was issued in exchange for Stella Series D Preferred Stock, a portion of which was owned by a related party investor who is a majority shareholder of Stella Diagnostics, Inc. and has board representation.
• Consulting fees of $190,000 were incurred to members of the Board of Directors during the nine months ended September 30, 2025.
• Consulting fees of $75,000 were incurred to members of the Board of Directors for the period from February 14, 2024, to September 30, 2024.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the conversion of Series E Preferred Stock and future capital raises. The reverse stock split aims to improve stock price and liquidity but carries risks of further price decline and negative investor perception. Voting power may be diluted by an increased number of authorized but unissued shares.
• **Employees**: The proposed increase in the equity incentive plan is designed to attract and retain key talent, aligning their interests with the company's long-term success through equity compensation.
• **Series E Preferred Stock Investors**: Their ability to convert preferred stock into common stock at potentially favorable prices is contingent on stockholder approval. Failure to approve Proposal No. 2 could restrict their conversion rights and impact the company's ability to secure future financing.
• **Creditors**: The company's ability to raise capital and fund operations directly impacts its financial stability and ability to meet obligations.

Next Steps

• Hold the 2025 Special Meeting of Stockholders on December 19, 2025, to vote on the proposed amendments and approvals.
• If Proposal No. 1 (Reverse Stock Split) is approved, the Board will determine the exact ratio (within the 1-for-40 to 1-for-150 range) and timing for its implementation within one year.
• File a Current Report on Form 8-K with the SEC within four business days after the Special Meeting to announce preliminary voting results, and an amended 8-K for final results if not immediately available.
• Continue to seek additional financing transactions through the remainder of 2025 and throughout 2026 to fund planned business operations and clinical trials.
• Advance the drug candidate CER-1236 into clinical development.
• Seek special designations or accelerated approvals for drug candidates for various indications.
• Grow a sales team for the commercialization of CER-1236, if approved.

Key Dates

Recommendation

The company is in a highly distressed state, evidenced by its delisting from Nasdaq and current trading on the OTC Pink Sheets at a very low share price. The proposed reverse stock split is a reactive measure with no guarantee of sustained success, as previous splits have not prevented further value erosion. The approval of the Series E preferred stock conversion, while necessary for immediate financing, introduces substantial potential for further dilution. The ongoing need for capital, coupled with significant operational risks inherent in biotech development and the company's current market challenges, indicates a high level of uncertainty and downside risk. The overall situation suggests a company struggling for viability, making it a high-risk investment with a strong likelihood of further value erosion for current shareholders.

Keywords

CERo Therapeutics, Reverse Stock Split, Nasdaq Listing, Equity Incentive Plan, Series E Preferred Stock, Private Placement, Biotechnology, SEC Filing, Corporate Governance, Stock Dilution, Capital Raise, Shareholder Meeting, CERO